| Company/Division name | Simtra BioPharma Solutions |
| Parent company | Advent International and Warburg Pincus |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2024 |
| Year reshoring implemented or to be implemented: | 2025 |
| Capital investment ($): | 250 |
| City reshored to: | Bloomington |
| State(s) reshored to: | IN |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals, Medical Equipment & Supplies |
| Product(s) reshored | Sterile Fill/Finish Manufacturing |
| What domestic positive factors made reshoring more attractive? | Better Control of Process/Delivery/Factory, Customization/Flexibility, Higher productivity, Manufacturing/engineering joint innovation (R&D) |
